doi: 10.1023/A:1008053913764.
The role of oncogenes in drug resistance
Affiliations
- PMID: 19002799
- PMCID: PMC3449565
- DOI: 10.1023/A:1008053913764
Item in Clipboard
The role of oncogenes in drug resistance
Cytotechnology.
1998 Sep.
Abstract
Increasing evidences indicate that oncogenes can directly or indirectly impact on cancer-cell drug resistance. This chapter provides a conceptual review regarding the role of oncogenes in drug resistance. The review is focused on drug resistance mediated by oncogenes encoding growth factor receptors, signaling molecules, transcription factors, cell-cycle regulators, and apoptosis regulators. It is my hope that better undertsnading on the role of oncogenes in drug resistance will invoke ideas on new approaches to enhance the cytotoxicity of the standard chemotherapeutic agents by functional perturbation of resistance-inducing oncogenes.
Similar articles
-
Cisplatin resistance and oncogenes--a review.Anticancer Drugs. 2000 Apr;11(4):225-36. doi: 10.1097/00001813-200004000-00001. Anticancer Drugs. 2000. PMID: 10898536 Review.
-
Oncogenes as novel targets for cancer therapy (part III): transcription factors.Am J Pharmacogenomics. 2005;5(5):327-38. doi: 10.2165/00129785-200505050-00005. Am J Pharmacogenomics. 2005. PMID: 16196502 Review.
-
Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.Stem Cells. 1994 Jul;12(4):352-69. doi: 10.1002/stem.5530120402. Stem Cells. 1994. PMID: 7951003 Review.
-
Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis.Am J Pharmacogenomics. 2005;5(6):397-407. doi: 10.2165/00129785-200505060-00006. Am J Pharmacogenomics. 2005. PMID: 16336004 Review.
-
Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules.Am J Pharmacogenomics. 2005;5(4):247-57. doi: 10.2165/00129785-200505040-00005. Am J Pharmacogenomics. 2005. PMID: 16078861 Review.
Cited by
-
Proteomic analysis of cell lines to identify the irinotecan resistance proteins.J Biosci. 2010 Dec;35(4):557-64. doi: 10.1007/s12038-010-0064-9. J Biosci. 2010. PMID: 21289438
-
Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches.Front Oncol. 2022 Jun 23;12:891652. doi: 10.3389/fonc.2022.891652. eCollection 2022. Front Oncol. 2022. PMID: 35814435 Free PMC article. Review.
-
Oncogenes associated with drug resistance in ovarian cancer.J Cancer Res Clin Oncol. 2015 Mar;141(3):381-95. doi: 10.1007/s00432-014-1765-5. Epub 2014 Jul 6. J Cancer Res Clin Oncol. 2015. PMID: 24997551 Free PMC article. Review.
References
-
- Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst. 1988;80:1605–1611. - PubMed
-
- Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ. p185c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res. 1994;54:3758–3765. - PubMed
-
- Bartkova J, Lukas J, Muller H, Strauss M, Gusterson B, Bartek J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Research. 1995;55:949–56. - PubMed
LinkOut - more resources
Full Text Sources
